Fludara Infusion
Fludarabin Phosphate
50 mg/2 ml
Synovia Pharma PLC.
| Pack size | 5's pack |
|---|---|
| Unite Price | 7422.57 BDT |
Indications
Fludara Infusion is used for:
Chronic lymphocytic leukaemia
Adult Dose
B-Cell Chronic Lymphocytic Leukemia
25 mg/sq.meter IV infusion over 30 minutes qD x5 days (up to 30 mg/sq.meter)
40 mg/sq.meter PO x5 days
Repeat q28Days
Child Dose
Safety and efficacy not established
Renal Dose
Renal impairment
CrCl 30-70 mL/min: reduce by 20%
CrCl <30 mL/min: IV not recommended; PO reduce 50%
Administration
IV Preparation
Reconstitute powder for inj with 2 mL SWI to result in a concentration of 25 mg/mL
Standard IV dilution: dose/100 mL D5W or NS
IV Administration
IV infusion over 30 min recommended by Mfr; has been given as continuous infusion or by rapid injection but risk of toxicity may be higher
Contra Indications
Renal impairment (CrCl <30 mL/min); decompensated haemolytic anaemia. Pregnancy and lactation. Concomitant use of live vaccines.
Precautions
Routine monitoring of blood counts and Hb conc. Monitor for signs of autoimmune haemolytic anaemia; elderly. Avoid contact with skin and eyes; avoid inhalation. Myelosuppression may be cumulative and severe increasing risk of opportunistic infections. Increased risk of tumour lysis syndrome in patients with high tumour burden.
Lactation: not known if excreted in breast milk, do not nurse
Pregnancy-Lactation
Pregnancy Category: D
Lactation: not known if excreted in breast milk, do not nurse
Interactions
Co-administration with pentostatin may lead to pulmonary toxicity. Reduced metabolic activation of fludarabine with cytarabine. Reduced therapeutic efficacy with dipyridamole and other adenosine uptake inhibitors.
Side Effects
Side effects of Fludarabin Phosphate :
>10%
Fever (69%), Objective weakness (65%), Anemia (60%), Neutropenia (60%), Thrombocytopenia (55%), Leukopenia (partly therapeutic), Infection (44%-not necessarily drug-induced), Cough (44%), Pain (44%), Fatigue (38%), N/V (36%), Anorexia (34%), Malaise (22%), Dyspnea (22%), Pneumonia (9-22%), Edema (19%), Myalgia (16%), URI (16%), UTI (15%), Rash (15%), Diarrhea (15%), Visual disturbances (15%), Diaphoresis (13%), GI bleeding (13%), Paresthesia (12%)
1-10% (selected)
Abdominal pain (10%), Back pain (9%), Headache (9%), Pharyngitis (9%), Stomatitis (9%), Flu like syndrome (5-9%), Malaise (6%), Angina (6%), Hearing Loss (2-6%), Peripheral edema (7%), Alopecia (3%), Constipation (1-3%), Arrhythmia (3%), DVT (1%)
Potentially Fatal: Myelosuppression. Fatal autoimmune haemolytic anemia.
Mode of Action
Fludarabine is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP which inhibits DNA polymerase and ribonucleotide reductase resulting in inhibition of DNA synthesis leading to cell death.
Note
Fludara 50 mg/2 ml Infusion generic name is Fludarabin Phosphate. Fludara 50 mg/2 ml Infusion is manufactured by Synovia Pharma PLC.Fludara is availble in all over Bangladesh.
Mes BD drug index information on Fludara Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.